Novo Nordisk sues Eli Lilly over misleading GLP-1 drug ads
On July 21, 2026, Novo Nordisk filed a federal lawsuit in the U.S. District Court for the District of New Jersey against Eli Lilly, alleging false advertising for its obesity drug Zepbound and diabetes drug Mounjaro. Novo claims Lilly’s ads use outdated clinical data, comparing higher doses of Lilly’s drugs to lower doses of Novo’s Wegovy and Ozempic, while omitting newer data on Novo’s higher-dose Wegovy (7.2 mg) showing comparable weight loss. Novo seeks a permanent injunction, corrective advertising, and financial damages. Lilly defends its ads as based on head-to-head trial evidence. The case underscores fierce competition in the $120 billion global obesity drug market.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection
Cross-source coverage
Wire timeline
Novo Nordisk seeks court order to halt Eli Lilly weight-loss drug advertisements
Novo Nordisk has asked a U.S. court for a preliminary injunction to immediately block Eli Lilly's weight-loss and diabetes drug advertisements, escalating their legal dispute. The Danish drugmaker filed a lawsuit earlier this week alleging that Lilly's marketing materials mislead consumers when comparing the companies' obesity and diabetes treatments. Novo had warned it would seek judicial intervention if the ads were not voluntarily withdrawn. The legal action comes as competition intensifies in the rapidly expanding obesity drug market, which analysts expect to exceed $100 billion in the U.S. by the end of the decade. Eli Lilly has denied any wrongdoing, stating it stands behind its advertising practices and intends to vigorously defend itself against Novo Nordisk's claims.
Novo Nordisk sues Eli Lilly over alleged misleading advertising of weight loss drugs
Novo Nordisk has filed a lawsuit against Eli Lilly in the US, accusing its rival of running a deceptive advertising campaign that misleads consumers about the comparative efficacy of their respective obesity and diabetes drugs. Novo claims Lilly's ads rely on outdated clinical studies to suggest that Lilly's tirzepatide (Mounjaro/Zepbound) outperforms Novo's semaglutide (Ozempic/Wegovy) in average weight loss. Specifically, Novo objects to Lilly omitting data on the highest 7.2mg dose of Wegovy, which showed 19% average weight loss, compared to Zepbound's 20.9% at its highest dose, noting no head-to-head trial has compared the highest doses. Novo seeks a permanent injunction to remove the ads and run corrective advertising. Lilly defends its ads as truthful and based on the SURMOUNT-5 study, which compared lower doses. The lawsuit comes amid heightened US scrutiny of direct-to-consumer drug advertising, following a 2025 presidential directive to crack down on misleading pharma ads.
Novo Nordisk sues Eli Lilly over GLP-1 drug advertising claims
Novo Nordisk has filed a federal lawsuit against Eli Lilly in the US District Court for the District of New Jersey, alleging that Lilly's advertising campaigns for its GLP-1 drugs Zepbound and Mounjaro mislead consumers by using outdated clinical trial data. Novo claims Lilly compares the highest approved doses of its drugs with lower doses of Novo's treatments, excluding newer data from higher-dose versions of Wegovy and Ozempic. The lawsuit seeks to permanently stop the disputed advertisements, require corrective advertising, and award financial damages. Novo's group general counsel stated the ads leave consumers with an inaccurate impression of superiority. Lilly defended its practices, stating its comparisons are based on direct head-to-head clinical trial evidence and that it will vigorously defend against the lawsuit. The case highlights intensifying competition in the weight-loss and diabetes treatment market.
Show 5 older updatesHide older updates
Novo Nordisk sues Eli Lilly over GLP-1 drug advertising claims
Novo Nordisk has filed a federal lawsuit against Eli Lilly in the US District Court for the District of New Jersey, alleging that Lilly's advertising campaigns for its GLP-1 drugs Zepbound and Mounjaro mislead consumers by using outdated clinical trial data and comparing higher doses of Lilly's drugs with lower doses of Novo's treatments. Novo claims the ads create an inaccurate impression that Lilly's medicines are superior for weight loss, while newer data shows comparable outcomes at higher doses. Specifically, the lawsuit targets comparisons of Zepbound 10 mg and 15 mg with Wegovy 1.7 mg and 2.4 mg, excluding data from Wegovy's newer 7.2 mg dose. Novo seeks a permanent injunction, corrective advertising, and financial damages. Lilly defends its advertising as truthful and based on the only direct head-to-head clinical trial between the two medicines, vowing to vigorously defend the lawsuit. The case highlights intensifying competition in the weight-loss and diabetes drug market.
Novo Nordisk sues Eli Lilly over GLP-1 advertising claims in escalating legal battle
Novo Nordisk has filed a lawsuit against Eli Lilly in the U.S. District Court for the District of New Jersey, accusing its rival of false advertising and unfair competition in marketing their GLP-1 obesity and diabetes drugs. The complaint alleges that Lilly's direct-to-consumer ads for Zepbound and Mounjaro misrepresent clinical data by comparing higher doses of Lilly's drugs with lower doses of Novo's Wegovy and Ozempic, while omitting higher-dose versions like the newly approved 7.2 mg Wegovy. Novo claims it sent a cease-and-desist letter in April but Lilly only added an insufficient disclaimer. Novo seeks a permanent injunction, disgorgement of profits, and a corrective advertising campaign. The lawsuit highlights intensifying competition in the GLP-1 market as supply constraints ease and marketing battles escalate.
Novo Nordisk Sues Eli Lilly Over Allegedly Misleading GLP-1 Drug Ads
Novo Nordisk, the manufacturer of Ozempic, has filed a federal lawsuit against rival Eli Lilly, accusing the company of using intentionally selected outdated studies in advertising campaigns to exaggerate the efficacy of its GLP-1 products. The lawsuit, filed on Tuesday, claims Eli Lilly's ads are misleading and deceptive. This legal action highlights the intense competition in the GLP-1 drug market, which includes popular diabetes and weight-loss medications. The case is still developing, with further details expected as it progresses through the court system.
Novo Nordisk sues Eli Lilly over misleading weight loss drug ads
Novo Nordisk filed a lawsuit against Eli Lilly on July 21, 2026, alleging that advertising campaigns for Lilly's obesity drug Zepbound and diabetes drug Mounjaro mislead consumers by using outdated clinical data to suggest those treatments are more effective than Novo's rival injections. The suit, filed in the U.S. District Court for the District of New Jersey, seeks a permanent court order prohibiting the ads and compelling corrective advertising, along with financial damages. Novo claims that Lilly's ads compare highest doses of Lilly's drugs to lower doses of Novo's treatments, omitting newer data on Novo's higher-dose Wegovy (7.2 mg), which showed comparable weight loss results. Novo sent a cease-and-desist letter in April, but Lilly did not respond. The lawsuit comes as Novo works to recover market share lost to Lilly in the rapidly growing global obesity drug market, projected to reach $120 billion by 2030.
Novo Nordisk sues Eli Lilly over misleading weight loss drug ads
Novo Nordisk filed a lawsuit against Eli Lilly on July 21, 2026, in the U.S. District Court for the District of New Jersey, alleging that advertising campaigns for Lilly's obesity drug Zepbound and diabetes drug Mounjaro mislead consumers by using outdated clinical data. The suit claims Lilly's ads compare the highest doses of its drugs to lower doses of Novo's treatments, omitting newer data on Novo's higher-dose Wegovy (7.2 mg), which showed average weight loss of 47 pounds—comparable to Zepbound's 50 pounds. Novo seeks a permanent court order to halt the ads, corrective advertising, and financial damages. It previously sent a cease-and-desist letter in April. The lawsuit invokes the Lanham Act and other federal and state statutes. The case comes as Novo works to recover market share lost to Lilly in the rapidly growing global obesity drug market, projected to reach $120 billion by 2030.